Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ALLO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ALLO

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Allogene Therapeutics Inc

ALLO
Current price
1.24 USD -0.05 USD (-3.88%)
Last closed 1.29 USD
ISIN US0197701065
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 275 601 056 USD
Yield for 12 month -64.57 %
1Y
3Y
5Y
10Y
15Y
ALLO
21.11.2021 - 28.11.2021

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Address: 210 East Grand Avenue, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

8.15 USD

P/E Ratio

Dividend Yield

Financials ALLO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ALLO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+22 000 USD

Last Year

+95 000 USD

Current Quarter

Last Quarter

-22 000 USD

Current Year

-192 277 000 USD

Last Year

+95 000 USD

Current Quarter

Last Quarter

-3 233 000 USD
EBITDA -239 986 000 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -28.92 %
PEG Ratio
Return On Equity TTM -59.60 %
Wall Street Target Price 8.15 USD
Revenue TTM
Book Value 1.76 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM -190 240 000 USD
Earnings per share -1.22 USD
Diluted Eps TTM -1.22 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation ALLO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3 859.62
Price Sales TTM 11 631.14
Enterprise Value EBITDA -1.04
Price Book MRQ 0.69

Technical Indicators ALLO

For 52 Weeks

0.86 USD 3.78 USD
50 Day MA 1.26 USD
Shares Short Prior Month 26 041 918
200 Day MA 1.90 USD
Short Ratio 7.91
Shares Short 26 572 188
Short Percent 14.42 %